secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001104659-22-128050
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics changes Chairman; Robert Ingram resigns, Mark Velleca appointed
--------------------------------------------------------------------------------

- Robert A. Ingram resigned as Chairman and Board member effective Dec 13, 2022; no disagreement with company.
- Mark A. Velleca, M.D., Ph.D. appointed Chairman of the Board on Dec 15, 2022.
- Board size reduced from 10 to 9 members upon Ingram's resignation.
- Velleca has been a board member since Aug 2021, formerly CEO of G1 Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/tm2232856d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-128050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer